Showing 1 - 9 of 9
Persistent link: https://www.econbiz.de/10008826072
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...
Persistent link: https://www.econbiz.de/10009492625
Persistent link: https://www.econbiz.de/10011404644
Wie funktioniert Gesundheitspolitik anderswo und warum? Seit März 2003 berichten Experten aus sechzehn Industrieländern zweimal jährlich zu aktuellen Entwicklungen in der Gesundheitspolitik. Schwerpunkte des vorliegenden zweiten Reports "Gesundheitspolitik in Industrieländern" (Zeitraum...
Persistent link: https://www.econbiz.de/10001959637
Since their introduction in 1993, the structure of physician drug budgets in Germany has changed frequently. Although highly disputed, they have limited the pharmaceutical expenditure of the Statutory Health Insurance Scheme for nearly one decade. This raises the question of how these savings...
Persistent link: https://www.econbiz.de/10013146564
Persistent link: https://www.econbiz.de/10011688008
Rising pharmaceutical expenditure has become a major concern for policy makers in Germany over recent years. Therefore, the pharmaceutical market has been increasingly targeted by different kinds of regulation, focussing on both the supply and the demand side, using price, volume and spending...
Persistent link: https://www.econbiz.de/10014196884
OBJECTIVE: To examine the price reactions of German pharmacies to changes made to OTC drug regulations in 2004. Prior to these changes, regulations guaranteed identical prices in all German pharmacies. METHODS: Two years after market deregulation, 256 pharmacies were surveyed to determine the...
Persistent link: https://www.econbiz.de/10014196889
Persistent link: https://www.econbiz.de/10013360312